About ARAV

Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan, a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of GHD in children and adults. Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving adherence and, therefore, treatment outcomes.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ARAV is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
VTI Vanguard Total Stock Market ETF 108.6 B 1.086E+11 3,570 3570 0.0% 0 47 K 47415
VXF Vanguard Extended Market ETF 6.5 B 6.5E+09 3,237 3237 0.0% 1E-05 51 K 51282
ITOT iShares Core S&P Total U.S. Stock Market ETF 21.0 B 2.09757E+10 3,548 3548 0.0% 0 10 K 9794
IWC iShares Microcap ETF 850.6 M 8.50572E+08 1,426 1426 0.01% 0.0001 86 K 86346
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 2.1 B 2.1E+09 1,002 1002 0.0% 1.76869E-05 38 K 37596